Autophagy Modulators

Autophagy, a fundamental catabolic process, involves the degradation and recycling of cellular components through lysosomes, crucial for maintaining cellular homeostasis, responding to stress, and recycling nutrients. This intricate pathway is initiated by the ULK1 complex, followed by the nucleation of the autophagosome through the Beclin-1/VPS34 complex, LC3 lipidation, and subsequent autophagosome formation and fusion with lysosomes. Modulators of Autophagy can either induce (activators) or inhibit (blockers) this process, making them attractive therapeutic targets. Dysregulated autophagy is implicated in a wide spectrum of diseases. In cancer, autophagy exhibits a dual role; it can act as a tumor suppressor in early stages but often promotes tumor survival and resistance to therapy in established cancers.

In neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's, impaired autophagy leads to the accumulation of misfolded proteins and cellular debris. It also plays roles in infectious diseases, metabolic disorders such as diabetes and obesity, inflammatory conditions like Crohn's disease, and the aging process itself, where autophagy declines. Research into autophagy modulators has seen significant progress. Chloroquine (CQ) and hydroxychloroquine (HCQ), approved antimalarials and autoimmune drugs, are widely repurposed as autophagy inhibitors in cancer clinical trials (Phase I-III). They primarily act by blocking autophagosome-lysosome fusion, aiming to enhance the efficacy of conventional chemotherapy and radiotherapy.

Beyond these lysosomotropic agents, other inhibitors target specific steps: VPS34 inhibitors like SAR405 and SBI-0206965, and ULK1/2 inhibitors such as MRT68921 and SBI-0206965, are in preclinical development. Autophagy activators, including rapamycin (an mTOR inhibitor that indirectly activates autophagy), trehalose, and carbamazepine, are being explored in preclinical and early clinical stages for neurodegenerative diseases. Inhibitors are broadly classified by their target (e.g., lysosomotropic agents, VPS34 inhibitors, ULK1/2 inhibitors, ATG protein inhibitors) or by their mechanism (e.g., fusion inhibitors, initiation inhibitors, elongation inhibitors). Key research tools include Bafilomycin A1 (a lysosomal acidification inhibitor), 3-MA (a PI3K inhibitor that inhibits early autophagy), and Torin 1/2 (mTOR inhibitors that activate autophagy). Challenges in developing autophagy modulators include achieving high specificity, addressing the context-dependent dual role of autophagy in cancer, managing potential off-target effects of broad-spectrum agents like CQ/HCQ, and accurately monitoring autophagy flux in vivo.

Combination therapy is a major strategy, particularly in oncology, where autophagy inhibitors are frequently combined with conventional chemotherapies, targeted therapies, or immunotherapies to overcome resistance. Similarly, autophagy activators are being investigated in combination with proteasome inhibitors for neurodegenerative conditions, highlighting the versatile therapeutic potential of modulating this essential cellular process.

10058-F4 Inhibits c-Myc Max Heterodimerization via Extended Conformational Selection
10058-F4 Inhibits c-Myc Max Heterodimerization via Extended Conformational Selection
AS1842856 Inhibits FOXO3a Mediated Apoptosis in ACADL Expressing Lung Adenocarcinoma
AS1842856 Inhibits FOXO3a Mediated Apoptosis in ACADL Expressing Lung Adenocarcinoma
DMOG (Dimethyloxallyl Glycine) Hydroxylase inhibitor Stabilizes HIF-1α to Potentiate TGF-β1-Mediated Myocardial Fibrosis
DMOG (Dimethyloxallyl Glycine) Hydroxylase inhibitor Stabilizes HIF-1α to Potentiate TGF-β1-Mediated Myocardial Fibrosis
DMH1 TGF-beta/Smad inhibitor Engagement of ALK2 Kinase Pocket
DMH1 TGF-beta/Smad inhibitor Engagement of ALK2 Kinase Pocket
Bafilomycin A1 (Baf-A1) from Selleck V-ATPase inhibition exacerbates NaIO3 cytotoxicity in ARPE-19 cells
Bafilomycin A1 (Baf-A1) from Selleck V-ATPase inhibition exacerbates NaIO3 cytotoxicity in ARPE-19 cells
PF-4708671 S6 Kinase inhibitor Targets p70S6K to Suppress Non-Small Cell Lung Cancer Growth
PF-4708671 S6 Kinase inhibitor Targets p70S6K to Suppress Non-Small Cell Lung Cancer Growth
Troglitazone (CS-045) targeting PPAR-γ regulates metabolic pathways and cutaneous inflammatory cascades
Troglitazone (CS-045) targeting PPAR-γ regulates metabolic pathways and cutaneous inflammatory cascades
LY3009120 Inhibits c-Raf ERK Signaling to Reverse DOCK1-Driven Endometrial Cancer Progression
LY3009120 Inhibits c-Raf ERK Signaling to Reverse DOCK1-Driven Endometrial Cancer Progression
BI-D1870 inhibitor blocks RSK4 signaling to attenuate renal cell carcinoma invasion
BI-D1870 inhibitor blocks RSK4 signaling to attenuate renal cell carcinoma invasion
Topotecan HCl Inhalation Enhances Targeted Topoisomerase I Inhibition in Lung Cancer Models
Topotecan HCl Inhalation Enhances Targeted Topoisomerase I Inhibition in Lung Cancer Models
Sorafenib Tosylate (BAY 43-9006) Multikinase Inhibition via Sodium Selenite Nanoparticles in Hepatocellular Carcinoma
Sorafenib Tosylate (BAY 43-9006) Multikinase Inhibition via Sodium Selenite Nanoparticles in Hepatocellular Carcinoma
Celastrol (Tripterine) Attenuates Ischemia-Reperfusion Injury by Suppressing the HIF-1α/PDK1 Axis
Celastrol (Tripterine) Attenuates Ischemia-Reperfusion Injury by Suppressing the HIF-1α/PDK1 Axis
SKI-606 (Bosutinib) SKI606 Targeted BCR-ABL1 Kinase Inhibition and Adverse Pulmonary Profiles
SKI-606 (Bosutinib) SKI606 Targeted BCR-ABL1 Kinase Inhibition and Adverse Pulmonary Profiles
Entrectinib (Rxdx-101) Rxdx-101 Trk receptor targeting and cost-effectiveness in ROS1-positive NSCLC
Entrectinib (Rxdx-101) Rxdx-101 Trk receptor targeting and cost-effectiveness in ROS1-positive NSCLC